Expect Equity LLC Purchases New Position in Bruker Corporation $BRKR

Key Points

• Expect Equity LLC purchased 70,930 Bruker shares worth approximately $4.27 million in the second quarter, making Bruker its fifth-largest holding and representing 2.7% of its portfolio. Institutional investors collectively own 79.52% of the company.
• Bruker reported quarterly EPS of $0.49, exceeding estimates by $0.11, while revenue rose 5.2% year over year to $838.5 million, below consensus expectations. The company maintained fiscal 2026 EPS guidance of $2.10–$2.15.
• Shares opened at $56.85, near the analyst consensus target of $56.64. Analysts’ overall view is “Moderate Buy,” and Bruker declared a quarterly dividend of $0.05 per share, yielding approximately 0.4% annually.

Expect Equity LLC purchased a new stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 70,930 shares of the medical research company's stock, valued at approximately $4,269,000. Bruker comprises approximately 2.7% of Expect Equity LLC's investment portfolio, making the stock its 5th largest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. Los Angeles Capital Management LLC purchased a new position in shares of Bruker during the fourth quarter valued at approximately $26,000. Allworth Financial LP raised its holdings in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company's stock valued at $29,000 after acquiring an additional 257 shares in the last quarter. Essential Partners LLC purchased a new stake in Bruker in the first quarter worth $36,000. Global Retirement Partners LLC purchased a new stake in Bruker in the second quarter worth $38,000. Finally, Parallel Advisors LLC boosted its holdings in Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company's stock valued at $41,000 after acquiring an additional 479 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Bruker Price Performance

BRKR stock opened at $56.85 on Wednesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. The firm has a 50 day moving average price of $58.69 and a 200-day moving average price of $47.71. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $65.30. The firm has a market capitalization of $8.66 billion, a price-to-earnings ratio of -81.21, a PEG ratio of 1.74 and a beta of 1.28.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.11. The company had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm's quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts forecast that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 21st. Bruker's dividend payout ratio is currently -28.57%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on BRKR shares. Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a research report on Wednesday, August 5th. Citigroup dropped their target price on shares of Bruker from $60.00 to $53.00 and set a "hold" rating for the company in a research report on Wednesday, August 5th. Wall Street Zen raised shares of Bruker from a "hold" rating to a "buy" rating in a research note on Saturday, May 9th. UBS Group set a $60.00 price target on shares of Bruker in a research report on Wednesday, June 24th. Finally, JPMorgan Chase & Co. increased their price target on shares of Bruker from $55.00 to $65.00 and gave the stock an "overweight" rating in a research note on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Bruker currently has a consensus rating of "Moderate Buy" and a consensus target price of $56.64.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source